These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35777862)

  • 1. Overcoming the limitations of cytokines to improve cancer therapy.
    Di Trani CA; Cirella A; Arrizabalaga L; Fernandez-Sendin M; Bella A; Aranda F; Melero I; Berraondo P
    Int Rev Cell Mol Biol; 2022; 369():107-141. PubMed ID: 35777862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokines in clinical cancer immunotherapy.
    Berraondo P; Sanmamed MF; Ochoa MC; Etxeberria I; Aznar MA; Pérez-Gracia JL; Rodríguez-Ruiz ME; Ponz-Sarvise M; Castañón E; Melero I
    Br J Cancer; 2019 Jan; 120(1):6-15. PubMed ID: 30413827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering cytokines for cancer immunotherapy: a systematic review.
    Fu Y; Tang R; Zhao X
    Front Immunol; 2023; 14():1218082. PubMed ID: 37483629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
    Vijayakumar G; McCroskery S; Palese P
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Facts and Hopes on Chimeric Cytokine Agents for Cancer Immunotherapy.
    Ren Z; Zhang X; Fu YX
    Clin Cancer Res; 2024 May; 30(10):2025-2038. PubMed ID: 38190116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Facts and Hopes: Immunocytokines for Cancer Immunotherapy.
    Pabani A; Gainor JF
    Clin Cancer Res; 2023 Oct; 29(19):3841-3849. PubMed ID: 37227449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The present and future of immunocytokines for cancer treatment.
    Gout DY; Groen LS; van Egmond M
    Cell Mol Life Sci; 2022 Sep; 79(10):509. PubMed ID: 36066630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineered Cytokine Signaling to Improve CAR T Cell Effector Function.
    Bell M; Gottschalk S
    Front Immunol; 2021; 12():684642. PubMed ID: 34177932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
    Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
    Front Immunol; 2018; 9():2905. PubMed ID: 30619269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins.
    Xiang J
    Hum Antibodies; 1999; 9(1):23-36. PubMed ID: 10331183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
    Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
    Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
    [No Abstract]   [Full Text] [Related]  

  • 12. IL-10 in cancer: an essential thermostatic regulator between homeostatic immunity and inflammation - a comprehensive review.
    Rallis KS; Corrigan AE; Dadah H; Stanislovas J; Zamani P; Makker S; Szabados B; Sideris M
    Future Oncol; 2022 Sep; 18(29):3349-3365. PubMed ID: 36172856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimulating the Antitumor Immune Response Using Immunocytokines: A Preclinical and Clinical Overview.
    Boersma B; Poinot H; Pommier A
    Pharmaceutics; 2024 Jul; 16(8):. PubMed ID: 39204319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural products and their derivatives as immune check point inhibitors: Targeting cytokine/chemokine signalling in cancer.
    Gupta M; Chandan K; Sarwat M
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):214-232. PubMed ID: 35772610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Th1 cytokine-based immunotherapy for cancer.
    Xu HM
    Hepatobiliary Pancreat Dis Int; 2014 Oct; 13(5):482-94. PubMed ID: 25308358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-Homing Antibody-Cytokine Fusions for Cancer Therapy.
    Prodi E; Neri D; De Luca R
    Onco Targets Ther; 2024; 17():697-715. PubMed ID: 39224695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
    Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
    J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiation and Regulation of T
    Basu A; Ramamoorthi G; Albert G; Gallen C; Beyer A; Snyder C; Koski G; Disis ML; Czerniecki BJ; Kodumudi K
    Front Immunol; 2021; 12():669474. PubMed ID: 34012451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.